Azitra, Inc. to Present at Biotech Showcase 2025 Alongside the J.P. Morgan Annual Healthcare Conference

Core Viewpoint - Azitra, Inc. is set to present at the Biotech Showcase 2025, highlighting its innovative therapies for precision dermatology and engaging with investors and potential partners [1][2]. Company Overview - Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing therapies for precision dermatology, with its lead product ATR-12 targeting Netherton syndrome, a rare skin disease [4]. - ATR-12 is currently in a Phase 1b clinical trial for adult patients, while ATR-04 is being developed for EGFR inhibitor associated rash and has received Fast Track designation from the FDA [4]. - The company utilizes a proprietary platform of engineered proteins and a microbial library of approximately 1,500 bacterial strains, enhanced by AI and machine learning technologies [4]. Event Details - The Biotech Showcase 2025 will take place from January 13-15, 2025, in San Francisco, with Azitra's COO Travis Whitfill presenting on January 13 at 3:00 p.m. PT [2][3]. - Azitra's management team will conduct one-on-one meetings with registered investors to discuss the company's business strategy, recent achievements, and future milestones [2].